drugset / Trial / NCT03473496
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
Terminated
2 enrolled
Zhujiang Hospital
Nanfang Hospital, Southern Medical University · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe Third Affiliated Hospital of Southern Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy.The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, and several clinical trials have been reported in the treatment of multiple myeloma with CAR-T cells.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2020-01-31
- Completion
- 2020-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | 1e+06 cells/kg | — |
| Subject | BCMA CAR-T | Cell therapy | 1e+07 cells/kg | — |
| Subject | CD138-CART | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD138-CART | Cell therapy | 1e+07 cells/kg | — |
| Subject | CD38-CART | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD38-CART | Cell therapy | 1e+07 cells/kg | — |
| Subject | CD56-CART | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD56-CART | Cell therapy | 1e+07 cells/kg | — |